Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study

Felix Gerhardt, Daniel Dumitrescu, Carina Gärtner, Ralf Beccard, Thomas Viethen, Tilmann Kramer, Stephan Baldus, Martin Hellmich, Eckhard Schönau, Stephan Rosenkranz, Felix Gerhardt, Daniel Dumitrescu, Carina Gärtner, Ralf Beccard, Thomas Viethen, Tilmann Kramer, Stephan Baldus, Martin Hellmich, Eckhard Schönau, Stephan Rosenkranz

Abstract

Objective: In patients with pulmonary arterial hypertension (PAH), supportive therapies may be beneficial in addition to targeted medical treatment. Here, we evaluated the effectiveness and safety of oscillatory whole-body vibration (WBV) in patients on stable PAH therapy.

Methods: Twenty-two patients with PAH (mean PAP≥25 mm Hg and pulmonary arterial wedge pressure (PAWP)≤15 mm Hg) who were in world health organization (WHO)-Functional Class II or III and on stable PAH therapy for≥3 months, were randomised to receive WBV (16 sessions of 1-hour duration within 4 weeks) or to a control group, that subsequently received WBV. Follow-up measures included the 6-min walking distance (6MWD), cardiopulmonary exercise testing (CPET), echocardiography, muscle-power, and health-related quality of life (HRQoL; SF-36 and LPH questionnaires).

Results: When compared to the control group, patients receiving WBV exhibited a significant improvement in the primary endpoint, the 6MWD (+35.4±10.9 vs -4.4±7.6 m), resulting in a net benefit of 39.7±7.8 m (p=0.004). WBV was also associated with substantial improvements in CPET variables, muscle power, and HRQoL. The combined analysis of all patients (n=22) indicated significant net improvements versus baseline in the 6MWD (+38.6 m), peakVO2 (+65.7 mL/min), anaerobic threshold (+40.9 mL VO2/min), muscle power (+4.4%), and HRQoL (SF-36 +9.7, LPH -11.5 points) (all p<0.05). WBV was well tolerated in all patients, and no procedure-related severe adverse events (SAEs) occurred.

Conclusions: WBV substantially improves exercise capacity, physical performance, and HRQoL in patients with PAH who are on stable targeted therapy. This methodology may be utilised in structured training programmes, and may be feasible for continuous long-term physical exercise in these patients.

Trial registration number: NCT01763112; Results.

Conflict of interest statement

Competing interests: None declared.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Figures

Figure 1
Figure 1
Changes of the 6-min walking distance (6MWD). (A) Study design and treatment groups. (B) Relative change of the 6MWD as compared to baseline 1 in the ‘whole-body vibration (WBV) only’ and ‘Control-WBV’ groups (n=11 each) (p

Figure 2

Key exercise gas exchange parameters…

Figure 2

Key exercise gas exchange parameters obtained by cardiopulmonary exercise testing. Left and middle…

Figure 2
Key exercise gas exchange parameters obtained by cardiopulmonary exercise testing. Left and middle column: Display of all cases before and after ‘Whole-Body Vibration’ (WBV) in the ‘WBV only’ and ‘Control-WBV’ groups (each n=11). Box plots show the whole cohort (n=22) at baseline and at end of WBV. (A) Peak VO2. (B) Anaerobic threshold (AT). VO2, Oxygen uptake; AT, Anaerobic threshold.
Figure 2
Figure 2
Key exercise gas exchange parameters obtained by cardiopulmonary exercise testing. Left and middle column: Display of all cases before and after ‘Whole-Body Vibration’ (WBV) in the ‘WBV only’ and ‘Control-WBV’ groups (each n=11). Box plots show the whole cohort (n=22) at baseline and at end of WBV. (A) Peak VO2. (B) Anaerobic threshold (AT). VO2, Oxygen uptake; AT, Anaerobic threshold.

References

    1. Galiè N, Humbert M, Vachiery JL, et al. . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67–119. 10.1093/eurheartj/ehv317
    1. Rosenkranz S. Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options. Clin Res Cardiol 2015;104:197–207. 10.1007/s00392-014-0765-4
    1. Pulido T, Adzerikho I, Channick RN, et al. , for the SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809–18. 10.1056/NEJMoa1213917
    1. Galiè N, Barberà JA, Frost A, et al. . Initial use of Ambrisentan plus Tadalafil in pulmonary arterial hypertension. N Engl J Med 2015;379:834–44. 10.1056/NEJMoa1413687
    1. Sitbon O, Channick R, Chin KM, et al. . Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015;373:2522–33. 10.1056/NEJMoa1503184
    1. Mereles D, Ehlken N, Kreuscher S, et al. . Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006;114:1482–9. 10.1161/CIRCULATIONAHA.106.618397
    1. Weinstein AA, Chin LMK, Keyser RE, et al. . Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension. Respir Med 2013;107:778–84. 10.1016/j.rmed.2013.02.006
    1. Chan L, Chin LM, Kennedy M, et al. . Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. Chest 2013;143:333–43. 10.1378/chest.12-0993
    1. de Man FS, Handoko ML, Groepenhoff H, et al. . Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2009;34:669–75. 10.1183/09031936.00027909
    1. Ehlken N, Lichtblau M, Klose H, et al. . Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension: a prospective, randomized, controlled trial. Eur Heart J 2016;37:35–44. 10.1093/eurheartj/ehv337
    1. Grünig E, Ehlken N, Ghofrani A, et al. . Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. Respiration 2011;81:394–401. 10.1159/000322475
    1. Rittweger J, Beller G, Felsenberg D. Acute physiological effects of exhaustive whole-body vibration exercise in man. Clin Physiol 2000;20:134–42. 10.1046/j.1365-2281.2000.00238.x
    1. Bosco C, Colli R, Introini E, et al. . Adaptive responses of human skeletal muscle to vibration exposure. Clin Physiol 1999;19:183–7. 10.1046/j.1365-2281.1999.00155.x
    1. Pérez-Turpin JA, Zmijewski P, Jimenez-Olmedo JM, et al. . Effects of whole body vibration on strength and jumping performance in volleyball and beach volleyball players. Biol Sport 2014;31:239–45. 10.5604/20831862.1112435
    1. Bruyere O, Wuidart MA, Di Palma E, et al. . Controlled whole body vibration to decrease fall risk and improve health-related quality of life of nursing home residents. Arch Phys Med Rehabil 2005;86:303–7. 10.1016/j.apmr.2004.05.019
    1. Álvarez-Barbosa F, del Pozo-Cruz J, del Pozo-Cruz B, et al. . Effects of supervised whole body vibration exercise on fall risk factors, functional dependence and health-related quality of life in nursing home residents aged 80+. Maturitas 2014;79:456–63. 10.1016/j.maturitas.2014.09.010
    1. O'Keefe K, Orr R, Huang P, et al. . The effect of whole body vibration exposure on muscle function in children with cystic fibrosis: a pilot efficacy trial. J Clin Med Res 2013;5:205–16. 10.4021/jocmr1137w
    1. Kantele S, Karinkanta S, Sievänen H. Effects of long-term whole-body vibration training on mobility in patients with multiple sclerosis: a meta-analysis of randomized controlled trials. J Neurol Sci 2015;358:31–7. 10.1016/j.jns.2015.09.357
    1. Greulich T, Nell C, Koepke J, et al. . Benefits of whole body vibration training in patients hospitalised for COPD exacerbations—a randomized clinical trial. BMC Pulm Med 2014;14:60 10.1186/1471-2466-14-60
    1. Furness T, Joseph C, Naughton G, et al. . Benefits of whole-body vibration to people with COPD: a community-based efficacy trial. BMC Pulm Med 2014;14:80 10.1186/1471-2466-14-38
    1. Rauch F, Sievanen H, Boonen S, et al. . Reporting whole-body vibration intervention studies: recommendations of the International Society of Musculoskeletal and Neuronal Interactions. J Musculoskelet Neuronal Interact 2010;10:193–8.
    1. Rosenkranz S, Preston IR. Right heart catheterization: best practice and pitfalls in pulmonary hypertension. Eur Respir Rev 2015;24:642–52. 10.1183/16000617.0062-2015
    1. Rosenkranz S, Gibbs JSR, Wachter R, et al. . Left ventricular heart failure and pulmonary hypertension. Eur Heart J 2016;37:942–54. 10.1093/eurheartj/ehv512
    1. Lang RM, Badano LP, Mor-Avi V, et al. . Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imag 2015;16:233–71. 10.1093/ehjci/jev014
    1. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–17. 10.1164/ajrccm.166.1.at1102
    1. Wasserman K, Hansen JE, Sue DY, et al. . Measurements During Integrative Cardiopulmonary Exercise Testing. In: Principles of Exercise Testing and Interpretation. 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2012:71–103.
    1. Fricke O, Weidler J, Tutlewski B, et al. . Mechanography: a new device for the assessment of muscle function in pediatrics. Pediatr Res 2006;59:46–9. 10.1203/01.pdr.0000191580.07644.1c
    1. Mathai SC, Puhan MA, Lam D, et al. . The minimal important difference in the 6 minute walk test for patiens with pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:428–33. 10.1164/rccm.201203-0480OC
    1. Ghofrani HA, Galiè N, Grimminger F, et al. , for the PATENT Investigators. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330–40. 10.1056/NEJMoa1209655
    1. Rosenberger A, Liphardt AM, Bargmann A, et al. . EMG and heart rate responses decline within 5 days of daily whole-body vibration training with squatting. PLoS ONE 2014;9:e99060 10.1371/journal.pone.0099060
    1. Gloeckl R, Heinzelmann I, Seeberg S, et al. . Effects of complementary whole-body vibration training in patients after lung transplantation: a randomized, controlled trial. J Heart Lung Transplant 2015;34:1455–61. 10.1016/j.healun.2015.07.002
    1. Perchthaler D, Grau S, Hein T. Evaluation of a six-week whole-body vibration intervention on neuromuscular performance in older adults. J Strength Cond Res 2015;29:86–95. 10.1519/JSC.0000000000000608
    1. Kabitz HJ, Bremer HC, Schwoerer A, et al. . The combination of exercise and respiratory training improves respiratory muscle function in pulmonary hypertension. Lung 2014;192:321–8. 10.1007/s00408-013-9542-9

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi